How much funding has Umoja Biopharma raised?

Umoja Biopharma has raised $363.0M in total funding, most recently a Series C round.

Who are Umoja Biopharma's investors?

Umoja Biopharma's investors include DCVC (Data Collab), Double Point Ventures, MPM Capital, Qiming Venture Partners USA, ARK Invest, SoftBank.

When was Umoja Biopharma founded?

Umoja Biopharma was founded in 2018.

Where is Umoja Biopharma headquartered?

Umoja Biopharma is headquartered in San Francisco, California, United States.

What industry is Umoja Biopharma in?

Umoja Biopharma operates in Biotech, Healthcare.

How many employees does Umoja Biopharma have?

Umoja Biopharma has 51-200 employees.

Umoja Biopharma

Pioneering In Vivo CAR T Cell Therapies

San Francisco, United States · Founded 2018 · $363.0M raised

Biotech

Healthcare

Headquarters: San Francisco, California
Employees: 51–200
Founded: 2018
Business Model: B2B

Website: umoja-biopharma.com
Total Funding: $363.0M
Last Round: $100.0M Series CJan 2025
Rounds: 3

About

Umoja Biopharma is a clinical-stage biotechnology company developing in vivo CAR T cell therapies for cancer treatment. Its flagship VivoVec platform generates chimeric antigen receptor (CAR) T cells directly inside a patient's body, eliminating the weeks-to-months manufacturing process required by traditional ex vivo CAR T therapies. The company has also invested in its own in-house manufacturing capacity, giving it control over supply, cost, and quality as it advances its pipeline toward commercial launch.

Summary

Umoja Biopharma is a Biotech company based in San Francisco, United States, founded in 2018. It has raised $363.0M in total across 3 rounds, most recently a $100.0M Series C round in Jan 2025. Investors include DCVC (Data Collab), Double Point Ventures and MPM Capital.